Niki BioSolutions Regains Compliance with Nasdaq Minimum Bid Price Requirement

Niki BioSolutions, Inc. (formerly Aptorum Group Limited) reported that it has regained compliance with the Nasdaq minimum bid price requirement. On March 5, 2026, the company had received a deficiency notice from Nasdaq because its common stock had closed below the $1.00 per share minimum for 30 consecutive business days. To regain compliance, the stock was required to maintain a closing bid price of at least $1.00 for a minimum of ten consecutive business days. On August 4, 2026, Nasdaq notified the company that from July 21, 2026, to August 3, 2026, the stock successfully maintained a closing bid price at or above the $1.00 threshold. Consequently, the company has met the requirements of Nasdaq Listing Rule 5550(a)(2), and the listing deficiency matter is now closed. The company's common stock continues to trade on The Nasdaq Capital Market under the symbol 'NIKI'.